
zzso For adults with plaque zzso after failure of topical symptomatic treatments and zzso therapy, several systemic zzso agents are acceptable for severe disease: methotrexate, then zzso and possible a zzso alpha zzso zzso zzso zzso zzso is an inhibitor of zzso 12 and 23, which are believed to be implicated in the onset of zzso It is authorized in the European Union for patients who fail to respond to conventional systemic zzso zzso In one trial with a low level of evidence zzso 2 subcutaneous injections of zzso at an zzso of 4 weeks appeared to be statistically more effective than zzso subcutaneous injections of zzso for 12 zzso More patients achieved a zzso reduction in the score most widely used to evaluate the extent and intensity of plaque psoriasis zzso zzso zzso about zzso versus zzso The results beyond this period have not been zzso zzso Two zzso zzso zzso trials in a total of 1996 patients showed that at least two-thirds of patients treated with zzso achieved at least a zzso reduction in their zzso score versus fewer than zzso with zzso zzso In animal studies, zzso 12 and 23 zzso cause zzso There is therefore a high risk of cancer developing during prolonged treatment with zzso zzso The main adverse effects identified in clinical trials include infections, zzso zzso psychological disorders and development of zzso zzso zzso There is insufficient follow-up to evaluate the cardiac risks associated with zzso zzso As maintenance therapy, zzso is administered as one subcutaneous injection every 12 zzso This practical advantage compared to zzso alpha zzso must be weighed against the risks inherent in prolonged zzso zzso In zzso for symptomatic relief of patients whose psoriasis poses major problems despite treatment with zzso or zzso in the absence of a better alternative, it is better to use a zzso alpha zzso and to avoid exposing patients to the risks associated with zzso particularly its zzso zzso 

